Investors Overview

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases.

Collegium has developed a novel, patented, abuse-deterrent technology platform, DETERx®, designed to provide extended-release drug delivery, while safeguarding against common methods of abuse and tampering including crushing, chewing, heating and injecting.

Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. While abuse of Xtampza ER is still possible, FDA has determined that the product has abuse-deterrent properties. The Xtampza ER label supports alternate administration options, including, sprinkling the capsule contents on soft foods or into a cup, and then directly into the mouth, or through a gastrostomy or nasogastric feeding tube.

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

More »

Recent News

Date Title  
Toggle Summary Collegium Appoints Richard Malamut, M.D., as Chief Medical Officer
STOUGHTON, Mass. , April 02, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced the appointment of Richard Malamut , M.D., as the company’s first Chief Medical
Toggle Summary Collegium to Present at Upcoming Investor Conferences
STOUGHTON, Mass. , April 01, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will present at the following investor conferences in April: The H.C.
Toggle Summary Collegium Reports Fourth-Quarter and Full-Year 2018 Financial Results
Xtampza ® ER Prescriptions Grew 233% in 2018 Net Revenue Increased to $73.4 Million for Fourth Quarter 2018 and $280.4 Million for the Full Year Cash and Cash Equivalents were $146.6 million as of December 31, 2018 , exceeding year-end cash guidance of $145.0 million Conference call scheduled for
Upcoming Events
There are currently no events scheduled.
More »